Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
7.4
5.2
Journals
Cancers
Special Issues
Inflammatory and Immunological Markers in Liver Cancers
share announcement

Inflammatory and Immunological Markers in Liver Cancers

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Molecular Cancer Biology".

Deadline for manuscript submissions: 31 May 2024 | Viewed by 2839

Special Issue Editor

Dr. Andrea Dalbeni

E-Mail Website
Guest Editor
Section of General Medicine C and Liver Unit, University of Verona, Verona, Italy
Interests: cirrhosis; MAFLD/NAFLD; HCC; infections
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Liver cancer (hepatocellular and colangiocharcinoma) is the second-most-common cause of cancer deaths worldwide.

Inflammation has been recognized as sign of cancer and is known to play an important role in the deterioration and progression of most tumors, even those that have no visible signs of inflammation and infection.

Liver inflammation is regulated by chemokines, which regulate the migration and activities of hepatocytes, Kupffer cells, hepatic stellate cells, endothelial cells, and circulating immune cells.

Emerging experimental data indicate that the presence of a pre-existing intratumoral T-cell infiltration, interferon (IFN) signaling, checkpoint molecules (PD-1, PD-L1 expression), or high tumor mutational burden could favor a clinical response. In recent years, immune checkpoint inhibitors, which unleash the body’s own immune response to attack tumors by targeting regulatory pathways in T cells, have shown remarkable efficacy in liver cancers.

If the relationship between inflammatory factors, immunological setting, and liver cancers can be found, it may provide new directions for the treatment of liver cancer.

This Special Issue will focus on these aspects.

Dr. Andrea Dalbeni
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • inflammation
  • immunological state
  • Hepatocellular (HCC)
  • Colangiocharcinoma (CC)
  • nutrition
  • anti PD1

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

13 pages, 248 KiB  
Article
Increased Risk of Malignancy with Immunosuppression: A Population-Based Analysis of Texas Medicare Beneficiaries
by Luca Cicalese, Jordan R. Westra, Casey M. O’Connor and Yong-Fang Kuo
Cancers 2023, 15(12), 3144; https://doi.org/10.3390/cancers15123144 - 11 Jun 2023
Viewed by 1030
Abstract
Immunosuppressive drugs (IMD) are widely utilized to treat many autoimmune conditions and to prevent rejection in organ transplantation. Cancer has been associated with prolonged use of IMD in transplant patients. However, no detailed, systematic analysis of the risk of cancer has been performed [...] Read more.
Immunosuppressive drugs (IMD) are widely utilized to treat many autoimmune conditions and to prevent rejection in organ transplantation. Cancer has been associated with prolonged use of IMD in transplant patients. However, no detailed, systematic analysis of the risk of cancer has been performed in patients receiving IMD for any condition and duration. We analyzed Medicare data from Texas Medicare beneficiaries, regardless of their age, between 2007 and 2018, from the Texas Cancer Registry. We analyzed the data for the risk of cancer after IMD use associated with demographic characteristics, clinical conditions, and subsequent cancer type. Of 29,196 patients who used IMD for a variety of indications, 5684 developed cancer. The risk of cancer (standardized incidence ratio) was particularly high for liver (9.10), skin (7.95), lymphoma (4.89), and kidney (4.39). Patients receiving IMD had a four fold greater likelihood of developing cancer than the general population. This risk was higher within the first 3 years of IMD utilization and in patients younger than 65 years and minorities. This study shows that patients receiving IMD for any indications have a significantly increased risk of cancer, even with short-term use. Caution is needed for IMD use; in addition, an aggressive neoplastic diagnostic screening is warranted. Full article
(This article belongs to the Special Issue Inflammatory and Immunological Markers in Liver Cancers)
12 pages, 1328 KiB  
Article
Interleukin-6: A New Marker of Advanced-Sarcopenic HCC Cirrhotic Patients
by Andrea Dalbeni, Leonardo Antonio Natola, Marta Garbin, Mirko Zoncapè, Filippo Cattazzo, Anna Mantovani, Antonio Vella, Stefania Canè, Jasmin Kassem, Michele Bevilacqua, Simone Conci, Tommaso Campagnaro, Andrea Ruzzenente, Alessandra Auriemma, Alessandro Drudi, Giovanna Zanoni, Alfredo Guglielmi, Michele Milella and David Sacerdoti
Cancers 2023, 15(9), 2406; https://doi.org/10.3390/cancers15092406 - 22 Apr 2023
Cited by 2 | Viewed by 1459
Abstract
Hepatocellular carcinoma (HCC) is the major cause of liver-related death worldwide. Interleukin 6 (IL-6) promotes the growth of the HCC microenvironment. The correlation between Child–Pugh (CP) and HCC stage and between HCC stage and sarcopenia is still not clear. Our aim was to [...] Read more.
Hepatocellular carcinoma (HCC) is the major cause of liver-related death worldwide. Interleukin 6 (IL-6) promotes the growth of the HCC microenvironment. The correlation between Child–Pugh (CP) and HCC stage and between HCC stage and sarcopenia is still not clear. Our aim was to investigate whether IL-6 is correlated with HCC stage and could represent a diagnostic marker for sarcopenia. Ninety-three HCC cirrhotic patients in different stages, according to BCLC-2022 (stages A, B, and C), were enrolled. Anthropometric and biochemical parameters, comprehensive of IL-6, were collected. The skeletal muscle index (SMI) was measured using dedicated software on computer tomography (CT) images. IL-6 level was higher in advanced (BCLC C) compared to the early-intermediate (BCLC A-B) stages (21.4 vs. 7.7 pg/mL, p < 0.005). On multivariate analysis, IL-6 levels were statistically dependent on the degree of liver disease severity (CP score) and HCC stages (p = 0.001 and p = 0.044, respectively). Sarcopenic patients presented lower BMI (24.7 ± 5.3 vs. 28.5 ± 7.0), higher PMN/lymphocyte ratio (2.9 ± 2.4 vs. 2.3 ± 1.2) and increased values of log (IL-6) (1.3 ± 0.6 vs. 1.1 ± 0.3). Univariate logistic regression between sarcopenia and log (IL-6) showed a significant odds ratio (OR 14.88, p = 0.044) with an AUC of 0.72. IL-6 appears to be an effective biomarker for the diagnosis of advanced cirrhotic HCC. In addition, IL-6 could be considered a marker of cirrhotic HCC-related sarcopenia, suggesting further investigation with BIA- or CT-dedicated software. Full article
(This article belongs to the Special Issue Inflammatory and Immunological Markers in Liver Cancers)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop